CME Activities
CLICK ON STATES TO SEE GRAND ROUNDS ACTIVITIES
ONLINE ACTIVITIES
Optimal LDL-C Reductions in Patients with Atherosclerotic Cardiovascular Disease: Maximizing Clinical Benefit within the Department of Veterans Affairs
PROGRAM CHAIR & FACULTY PRESENTER
Christie M. Ballantyne, MD
Professor of Medicine
Chief of Cardiology & Cardiovascular Research
Director of the Clinic for Cardiometabolic Disease Prevention
Baylor College of Medicine
Houston, TX
TARGET AUDIENCE
This activity is intended for lipidologists, cardiologists, endocrinologists, and other healthcare professionals involved in the management of patients at high risk for CVD due to hypercholesterolemia.
LEARNING OBJECTIVES
After completing the CME activity, learners should be better able to:
- Explain how lowering LDL-C levels reduces residual CVD risk in patients with persistent hypercholesterolemia and at high risk for poor CV outcomes
- Review mechanisms of action, clinical profile, and the position of PCSK9 inhibitors in treatment regimens for patients with persistent hypercholesterolemia and at high risk for poor CV outcomes
- Apply best practices for the identification and management of patients with persistent hypercholesterolemia and at high risk for poor CV outcomes who are candidates for tailored, intensified lipid-lowering regimens based on clinical guidance, individual patient risk factors, comorbidities, and prior treatment responses
- Discuss the designs and results of long-term CV outcomes studies examining PCSK9 inhibitors in different patient populations with persistent hypercholesterolemia and at high risk for poor CV outcomes
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this web-based activity for a maximum of 0.75 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the management of patients at high risk for CVD due to hypercholesterolemia
CNE Credits: 0.75 ANCC Contact Hours.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.75 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Ballantyne reports for the past 12 months:
-Consultant for Abbott Diagnostic, Akcea, Amarin, Amgen, Arrowhead, Astra Zeneca, Boehringer Ingelheim, Corvidia, Denka Seiken, Esperion, Intercept, Janssen, Matinas BioPharma Inc, Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic, and Sanofi-Synthelabo
-Provisional patent for “Biomarkers to Improve Prediction of Heart Failure Risk” (patent no. 61721475) filed by Baylor College of Medicine and Roche
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures
2. Participate in the enduring activity
3. Complete the online evaluation
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: February 7, 2020
EXPIRATION DATE: February 7, 2021
Improving the Care of Patients with Persistent Hypercholesterolemia by Decreasing Cardiovascular Risk Using PCSK9 Inhibitors: A Comprehensive Infographic View
FACULTY
Michael Davidson, MD
Professor, Director of the Lipid Clinic
The University of Chicago
Pritzker School of Medicine
Chicago, Illinois
PROGRAM OVERVIEW
This enduring activity will cover the management of patients at high risk for developing cardiovascular disease (CVD) due to hypercholesterolemia.
TARGET AUDIENCE
This activity is intended for lipidologists, cardiologists, endocrinologists, and other healthcare professionals involved in the management of patients at high risk for developing CVD due to hypercholesterolemia.
LEARNING OBJECTIVES
After completing the CME activity, learners should be better able to:
- Explain how lowering LDL-C levels reduces residual CVD risk in patients with persistent hypercholesterolemia and at high risk for poor CV outcomes
- Review mechanisms of action, clinical profiles, and position in treatment regimens for PCSK9 inhibitors in patients with persistent hypercholesterolemia and at high risk for poor CV outcomes
- Apply best practices for the identification and management of patients with persistent hypercholesterolemia and at high risk for poor CV outcomes who are candidates for tailored, intensified lipid-lowering regimens based on clinical guidance, individual patient risk factors, comorbidities, and prior treatment responses
- Discuss the designs and results of long-term CV outcomes studies examining PCSK9 inhibitors in different patient populations with persistent hypercholesterolemia and at high risk for poor CV outcomes
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 0.75 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the care of patients at high risk for developing cardiovascular disease (CVD) due to hypercholesterolemia.
CNE Credits: 0.75 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.75 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
FACULTY
Dr. Davidson has received consulting fees from and serves on the speakers’ bureau for Amgen, Sanofi, Regeneron, Akcea, and Novo Nordisk.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
Brianna Hanson, Outcomes and Accreditation Coordinator for Med Learning Group, has nothing to disclose.
Marcello Morgan, MD, MPH, Medical Director, Scientific and Medical Services for Med Learning Group, has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: February 21, 2020
EXPIRATION DATE: February 21, 2021
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
GRAND ROUNDS
BOOTH TOUR
A Virtual Reality Learning Experience: Integrating GLP-1 Receptor Agonists into T2DM Practice—Why, When, and How
Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
